Another earlier memantine trial – the Benefit and Efficacy in Severely Demented patients during Treatment with Memantine (M-Best or 9403) study – enrolled participants with moderately severe AD as ...

This release is available in German. There is no scientific proof that patients with moderate or severe Alzheimer's disease benefit from drugs containing the agent memantine. This is the conclusion in ...

NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE: FRX) and Merz Pharmaceuticals GmbH announced today that NAMENDA XR (TM) (memantine hydrochloride) was approved by the U.S. Food and Drug ...

The regulatory approval of memantine for use in the symptomatic treatment of moderate to severe Alzheimer's disease has led to high hopes among patients and their families. However, many physicians ...

After the manufacturer of the Alzheimer's drug memantine submitted a supplementary analysis of study data, the German Institute for Quality and Efficiency in Health Care sees proof of a benefit of the ...

Memantine, a drug approved for the treatment of Alzheimer disease, appears safe and effective in patients with moderate to severe cases of the condition, according to a study in the January issue of ...

Donepezil, galantamine, rivastigmine and memantine are recommended as possible treatments for some people with Alzheimer's disease. You should be able to have donepezil, galantamine or rivastigmine if ...

Please provide your email address to receive an email when new articles are posted on . Response rates on the SRS-2 and CGI-S were significantly higher in those given memantine. Memantine was also ...

Protection of abstinent individuals from relapse is the main goal of drug dependence treatment. Relapse is frequently precipitated by exposure to small doses of the drug of abuse or exposure to the ...

For nearly a decade the conventional formulation of memantine has been helpful for treating patients with AD, especially those with advanced stages of the disease. Treatment with memantine has been ...

Forest and Merz Announce FDA Approval of NAMENDA XR for the Treatment of Moderate to Severe Dementia of the Alzheimer's Type NEW YORK, Jun 21, 2010 (BUSINESS WIRE ...